what is the difference between semaglutide and dulaglutide Frontiers Frontiers | Comparative effectiveness of
Description
In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4mg in patients with obesity was associated with a 22% reduction in the main 5-component kidney composite endpoint compared to patients on placebo.
Discover the most effective GLP-1 probiotics for weight loss, how they work, and their benefits
Methods: The Plan-Do-Study-Act (PDSA) model was used in the design of this QI project
Same molecule
